基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

未开盘 06-10 16:09:07

4.340

+0.040

+0.93%

最高4.400	最低4.010	成交量1,104万
今开4.400	昨收4.300	日振幅9.07%
总市值69.48亿	流通市值69.48亿	总股本16.01亿
成交额4,625万	换手率0.69%	流通股本16.01亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":4.34,"timestamp":1781078947007,"preClose":4.3,"halted":0,"volume":11043645,"delay":0,"changeRate":0.009302325581395357,"floatShares":1601000000,"shares":1601000000,"eps":-0.314752,"marketStatus":"未开盘","change":0.04,"latestTime":"06-10 16:09:07","open":4.4,"high":4.4,"low":4.01,"amount":46250373,"amplitude":0.090698,"askPrice":4.34,"askSize":297000,"bidPrice":4.31,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":-0.302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781141400000},"marketStatusCode":0,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":4.3,"openAndCloseTimeList":[[1781055000000,1781064000000],[1781067600000,1781078400000]],"volumeRatio":0.7462125085522927,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"2642742805","title":"执行董事兼首席执行官杨建新增持基石药业-B(02616)14.5万股 每股作价约4.26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642742805","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642742805?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:52","pubTimestamp":1781088749,"startTime":"0","endTime":"0","summary":"6月10日，执行董事兼首席执行官杨建新增持基石药业-B(02616)14.5万股，每股作价4.2593港元，总金额约为61.76万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260610/20260610185255_12629.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260610/20260610185255_12629.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","BK1161","BK1574","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148362","title":"康方新药取得历史性突破，为何蒸发百亿市值","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148362","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641148362?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:42","pubTimestamp":1780659720,"startTime":"0","endTime":"0","summary":"6月1日，康方生物开盘后一度涨超12%，然而高开低走，此后三日连续下跌，截至6月5日收盘，康方生物总市值862亿港元，数日内市值跌去超百亿。在康方生物的叙述中，这份登陆ASCO全体会议的临床数据堪称历史性突破。无可辩驳的是，康方生物的HARMONi-6已达到全部预期终点，取得显著阳性。股价为何下跌数据公布后3日，康方生物的市值跌去超百亿港元，截至发稿，总市值已不足千亿。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4225","LU2476274720.SGD","LU1794554557.SGD","LU0540923850.HKD","LU2488822045.USD","BK4211","06978","09926","PFS","BK4203","LU0348784397.USD","IE00B5MMRT66.SGD","LU0348825331.USD","LU2778985437.USD","LU2399975544.HKD","02616","LU0634319403.HKD","LU1720050803.USD","BK1574","LU0561508036.HKD","LU2476274308.USD","HR","BK1161","IE00BPRC5H50.USD","LU0348827113.USD","LU0348767384.USD","LU0417516902.SGD","BK4195","IE00B543WZ88.USD","LU1961090484.USD","LU0417516738.SGD","LU0348766576.USD","LU0348783233.USD","LU0348735423.USD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179641013","title":"基石药业-B5月股份变动月报表：股本略有增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1179641013","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179641013?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:41","pubTimestamp":1780562518,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年6月4日发布截至2026年5月31日的股份变动月报表。公告显示，公司于报告期内总股本较上月小幅增加，注册股本维持不变。以下为本次披露的要点：。本期公司注册股本为2,000,000,000股，每股面值为0.0001美元，总额200,000美元，与上月一致。截至5月末，已发行普通股股份数量由上月底的1,600,249,187股增至1,600,749,183股，增加499,996股；报告期内并无产生或注销库藏股。报告期内未涉及购回或赎回股份事项。本公告由公司董事李伟签署，公告日期为2026年6月4日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640138210","title":"杰富瑞(Jefferies)：高管增持彰显发展信心 CS2009临床数据亮眼确立BD预期 维持基石药业-B(02616)“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2640138210","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640138210?lang=zh_cn&edition=full","pubTime":"2026-06-04 08:38","pubTimestamp":1780533520,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，杰富瑞发布研报称，基石药业-B管理层增持计划印证公司对管线授权洽谈的信心。该行看好CS2009商业化与授权潜力，维持基石药业“买入”评级，目标价20港元，较现价有298%上涨空间。杰富瑞主要观点如下：管理层增持股份，看好CS2009商务授权前景公司管理层及董事会拟增持公司股票，充分印证管理层对管线BD进展的高度信心。临床数据证实CS2009可改善肿瘤微环境免疫抑制，让既往免疫治疗无效患者获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"杰富瑞(Jefferies)：高管增持彰显发展信心 CS2009临床数据亮眼确立BD预期 维持基石药业-B(02616)“买入”评级","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165373917","title":"基石药业-B宣布CEO、董事及高级管理层启动联合购股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1165373917","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165373917?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:40","pubTimestamp":1780483217,"startTime":"0","endTime":"0","summary":"基石药业-B（2616.HK）于6月3日宣布，其首席执行官、董事会成员及高级管理层已共同启动一项股份购买计划。根据该计划，相关人士拟自2026年6月起，在公开市场联合购入总计200万至500万股公司股份。\n此项联合购股行动彰显了公司核心管理层对基石药业-B未来长期发展前景的坚定信心，并体现了其与股东利益深度绑定的决心。管理层通过真金白银投入市场，直接参与股份增持，旨在向投资者传递积极的信号。\n计划的具体实施细节将遵循相关市场规则与披露要求。市场分析人士认为，此类内部人士的集体购股行为，通常被视作对公司内在价值和增长潜力的认可，可能对市场情绪产生正面影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640969903","title":"基石药业-B(02616)董事及高管拟增持200万股至500万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2640969903","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640969903?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:03","pubTimestamp":1780481018,"startTime":"0","endTime":"0","summary":"增持将于2026年6月起至刊发集团截至2026年6月30日止六个月的中期业绩禁售期开始前进行，增持股份总数为200万股至500万股公司股份。公司董事会认为，董事及高级管理层进行的股份增持，充分体现了彼等对公司作出的长期承诺以及对公司未来业务前景的坚定信心。董事会相信，该等增持行为符合公司及其股东的整体最佳利益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B(02616)董事及高管拟增持200万股至500万股公司股份","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199739469","title":"异动解读 | 竞争药物数据超预期引发担忧，基石药业-B盘中大跌8.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199739469","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199739469?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:23","pubTimestamp":1780385002,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中股价大幅下挫，跌幅一度达到8.64%，引起市场关注。消息面上，高盛在最新发布的报告中指出，公司股价此前已出现显著波动。这一强劲数据引发了市场对于基石药业核心在研产品CS2009未来市场竞争格局及监管审批路径的担忧，尽管高盛同时给予公司“买入”评级并认为CS2009的监管路径预期将保持清晰。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640990449","title":"高盛：发布ASCO后最新报告 给予基石药业-B(02616)“买入”评级 目标价为 9.44 港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640990449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640990449?lang=zh_cn&edition=full","pubTime":"2026-06-02 14:54","pubTimestamp":1780383286,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，给予基石药业-B“买入”评级，基于风险调整后DCF的12个月目标价为 9.44港元。该行重申对 CS2009 所展现的整体药物特性的积极看法，并强调执行是关键，因为基石药业的目标是在 2026 年底前启动首批 III 期 MRCT 并达成一项业务发展交易。该行重申 CS2009 总体耐受性良好，并预计在后期试验中具有相似的安全性特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176228064","title":"基石药业-B拟回购不超过已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176228064","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176228064?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:11","pubTimestamp":1780319492,"startTime":"0","endTime":"0","summary":"基石药业-B于6月1日发布公告，拟在股东周年大会上申请授权，回购不超过公司于股东大会通过当天已发行股本总数10%的股份。公司当前已发行股份总数约为1,600,749,183股，回购规模上限约为160,074,918股。股权登记截止日为6月23日，股东及股东代理人可于当天大会上就回购议案进行表决。董事会强调，此次回购将不会导致该公司公众持股比例低于香港联交所的最低持股要求。董事会认为，本次回购计划符合公司和股东的整体利益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B拟回购不超过已发行股本10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981923","title":"ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981923","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640981923?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:27","pubTimestamp":1780273622,"startTime":"0","endTime":"0","summary":"格隆汇6月1日丨基石药业-B宣布，公司核心资产CS2009的多项临床关键进展，于美国临床肿瘤学会年会上通过两份壁报正式发布，涵盖CS2009在一线及后线非小细胞肺癌和结直肠癌患者中的I/II期临床试验数据，以及晚期实体瘤患者更长随访后的成熟I期临床数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260601/32265512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","LU0266512127.USD","LU0456854461.SGD","CRC","02616","BK1574","BK4213"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B031HY20.USD","LU1880383366.USD","AGIX","ARTY","01877","BK1589","LU0348767384.USD","LU1993786604.SGD","LU2097828631.EUR","01801","LU0315179316.USD","CHAT","09995","01177","SG9999002562.SGD","LU0456846285.SGD","LU0516422952.EUR","LU0456827905.SGD","159992","LU1226288170.HKD","LU0856984785.SGD","02616","09688","LU1960683339.HKD","LU1152091168.USD","IE00BPRC5H50.USD","06185","LU1152091754.HKD","LU0561508036.HKD","BK1161","LU0572944931.SGD","LU0072913022.USD","LU0634319403.HKD","LU0348827113.USD","LU1226287792.SGD","LU1303224171.USD","BK1588","01093","LU0067412154.USD","LU1719994722.HKD","02269","LU0417516738.SGD","AIPO","LU0140636845.USD","LU0326950275.SGD","06160","02142","BK1583","09926","06978"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","01877","SG9999002562.SGD","01093","601066","LU0516423174.USD","BK1161","02142","IE00BZ08YR35.GBP","BK1588","LU0359202008.SGD","LU2097828474.EUR","LU2097828631.EUR","LU0588546209.SGD","LU0348827113.USD","LU1152091168.USD","LU1993786604.SGD","IE00B0JY6N72.USD","01801","LU1152091754.HKD","IE00BZ08YS42.EUR","LU0979878070.USD","01177","06160","02269","IE00B543WZ88.USD","LU0561508036.HKD","09926","LU1303224171.USD","LU2399975544.HKD","LU1969619763.USD","LU2097828557.USD","LU1242518857.USD","LU0516422952.EUR","159992","LU1242518931.SGD","09688","09995","LU1226287875.USD","LU0417516738.SGD","06978","IE00B5MMRT66.SGD","LU1688375341.USD","BK1141","LU0039217434.USD","LU0326950275.SGD","LU0456827905.SGD","BK1574","06185","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154471918","title":"异动解读 | 基石药业-B盘中大涨5.08%，拟回购股份及核心产品临床数据即将公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1154471918","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154471918?lang=zh_cn&edition=full","pubTime":"2026-05-14 11:41","pubTimestamp":1778730071,"startTime":"0","endTime":"0","summary":"基石药业-B(02616)今日盘中大涨5.08%，引起了市场的广泛关注。消息面上，基石药业-B发布公告，拟于公开市场上回购最多不超过1.36亿股股份，此举彰显了公司管理层及董事会对自身研发成果、商业化进展与长期业务发展的坚定信心，并体现了公司高度重视股东价值回报的理念。同时，公司核心产品CS2009（PD-1/VEGF/CTLA-4三特异性抗体）的最新临床数据即将于ASCO年会公布，这一进展进一步增强了市场对公司未来增长潜力的预期，从而推动了股价的上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635000432","title":"基石药业-B(02616)拟于公开市场上购回最多不超过1.36亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635000432","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635000432?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:58","pubTimestamp":1778666335,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，根据本公司股东于本公司2025年6月25日举行的股东周年大会上批准的购回股份的一般授权及(如适用)未来股东于本公司不时的股东大会上批准的购回股份的任何一般授权(购回授权)，其拟不时于公开市场上购回最多不超过1.36亿股股份。本公司核心产品CS2009(PD-1/VEGF/CTLA-4三特异性抗体)的最新临床数据即将于ASCO年会公布。适时实施购回股份计划，充分彰显本公司管理层及董事会对自身研发成果、商业化进展与长期业务发展的坚定信心。亦体现本公司高度重视股东价值回报、持续完善资本回馈机制的理念。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B(02616)拟于公开市场上购回最多不超过1.36亿股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634342270","title":"基石药业-B(02616)启动地产化普拉替尼胶囊全国商业化发货","url":"https://stock-news.laohu8.com/highlight/detail?id=2634342270","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634342270?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:08","pubTimestamp":1778458113,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司高选择性RET抑制剂普拉替尼胶囊的首批地产化产品已完成生产及放行，并正式启动全国商业化发货。受益于国家医保目录准入对患者可及性的显著提升，截至2026年4月，普拉替尼胶囊的终端销售量较去年同期快速增长超430%。基于这一增长趋势，预计2026年全年普拉替尼胶囊销售收入有望超过人民币3亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439948.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B(02616)启动地产化普拉替尼胶囊全国商业化发货","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125457924","title":"基石药业-B启动国产普拉替尼胶囊全国商业化供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1125457924","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125457924?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:01","pubTimestamp":1778457676,"startTime":"0","endTime":"0","summary":"基石药业-B宣布，其本土生产的普拉替尼胶囊已正式开始在全国范围内进行商业化供应。这一举措标志着该产品在中国市场进入全面商业化的新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120255555","title":"基石药业-B 4月新增1.24亿股，股本升至16.00亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1120255555","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120255555?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:06","pubTimestamp":1778144779,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年5月7日发布2026年4月股份变动月报。公告显示，公司截至本月末的注册股本仍为2,000,000,000股、面值0.0001美元，法定股本为200,000美元，均与上月保持不变。根据月报披露信息，4月末已发行股份由上月底的1,476,018,722股上升至1,600,249,187股，当月累计新增124,230,465股。截至月末，公司库存股份数为0股，未发生购回或注销行为。公司确认其已充分符合香港联交所相关上市规则、法律及监管要求，并表示上述股份发行及期权行使均经董事会正式授权和批准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177023630","title":"异动解读 | 基石药业-B盘中大跌5.17%，配股稀释与业绩亏损双重压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1177023630","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177023630?lang=zh_cn&edition=full","pubTime":"2026-04-28 15:27","pubTimestamp":1777361238,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大跌5.17%，引起了市场的广泛关注。消息面上，公司近期完成了大规模股份发行，根据配售协议以每股8.97港元的价格配发了约1.18亿股新股，占配发前已发行股本约7.99%，同时通过受限制股份奖励计划再发行了600万股。这使得公司股本在短期内显著扩大，股权稀释压力明显，且配售价较市价存在折价，导致市场抛压持续释放。此外，公司最新披露的年度业绩显示，其收入同比下滑33.8%至约2.70亿元人民币，年内亏损则从约0.91亿元大幅扩大至4.37亿元，研发投入也有所增加，经营压力上升。配股带来的稀释效应与基本面承压的双重因素叠加，共同导致了股价的下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159919357","title":"基石药业-B（02616）2025年业绩速览：收入下滑33.8%，差异化研发管线稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1159919357","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159919357?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:06","pubTimestamp":1777284381,"startTime":"0","endTime":"0","summary":"基石药业-B于2025年年度实现收入约2.70亿元人民币，较上一年度的4.07亿元减少33.8%，主要受商业化与授权收入下降影响。同期收入成本为2.18亿元，毛利约0.51亿元。研发投入增至3.12亿元，较此前1.35亿元大幅提升，主要因关键临床试验和新药项目加速推进。销售及市场推广开支约0.83亿元，行政开支约0.89亿元。整体来看，年内亏损从上一年度约0.91亿元扩大至4.37亿元，经营压力显著上升。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"基石药业-B（02616）2025年业绩速览：收入下滑33.8%，差异化研发管线稳步推进","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145260957","title":"异动解读 | 基石药业-B盘中大跌5.90%，大额配股稀释效应持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1145260957","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145260957?lang=zh_cn&edition=full","pubTime":"2026-04-24 10:04","pubTimestamp":1776996250,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大跌5.90%，引起了市场的广泛关注。消息面上，公司此前根据配售协议以每股8.97港元的价格配发及发行1.18亿股新股，占配发前已发行股本约7.99%，总筹资约10.53亿港元。此外，公司于4月23日通过受限制股份奖励计划再发行600万股新股。短期内大规模新股发行导致股本从约14.76亿股扩大至约16亿股，股权稀释压力显著，叠加配售价较当前股价存在折价，市场抛压持续释放。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":-0.1197},{"period":"1month","weight":-0.4852},{"period":"3month","weight":-0.3913},{"period":"6month","weight":-0.2908},{"period":"1year","weight":0.0046},{"period":"ytd","weight":-0.1765}],"compareEarnings":[{"period":"1week","weight":-0.0478},{"period":"1month","weight":-0.0757},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0604},{"period":"1year","weight":0.0101},{"period":"ytd","weight":-0.0477}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家主要从事肿瘤、自身免疫和炎症及其他关键疾病领域药物研发及销售的投资控股公司。该公司通过子公司主要从事生物制药产品的研发、药品的销售及提供其知识产权（IP）授权或商业化授权。该公司产品主要包括精准治疗药物“泰吉华”（阿伐替尼）及“普吉华”（普拉替尼）、以及“择捷美”（舒格利单抗）等。该公司还从事肿瘤免疫药物的开发及商业化。该公司主要在中国国内市场、以及中欧、东欧和瑞士等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.050688},{"month":2,"riseRate":0.428571,"avgChangeRate":0.069097},{"month":3,"riseRate":0.25,"avgChangeRate":-0.053883},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.031371},{"month":5,"riseRate":0.428571,"avgChangeRate":0.066954},{"month":6,"riseRate":0.625,"avgChangeRate":0.025018},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05639},{"month":8,"riseRate":0.428571,"avgChangeRate":0.079119},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.071005},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.012196},{"month":11,"riseRate":0.571429,"avgChangeRate":0.010396},{"month":12,"riseRate":0.428571,"avgChangeRate":0.004524}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}